Buyer/Partner (location)

Licensor/Partner
(location)

Value (M)

Type/product area

Terms/details

Date

november

Bellicum Pharmaceuticals Inc. (Houston)

Ospedale Pediatrico Bambino Gesù (OPBG; Rome)

N/A

Expanded collaboration focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum's Caspacide molecular safety switch technology

Bellicum agreed to provide undisclosed financial support to the venture in exchange for exclusive worldwide rights to commercialize certain cell therapies that are developed, while OPBG maintains rights for research purposes; OPBG agreed to manufacture European clinical trial supplies for the investigational programs, as well as Bellicum's BPX-701

11/2/16

Biogen Inc. (Cambridge, Mass.)

Absorption Systems Inc. (Exton, Pa.)

N/A

Renewed license for technology associated with the test system for drug transporters developed by Absorption Systems for another year

The MDR1-MDCK cell line is stably transfected with the human MDR1 gene, which codes for a protein known as multidrug-resistance protein, or P-glycoprotein

11/22/16

Celgene Corp. (Summit, N.J.)

Pharmakea Inc. (San Diego)

$9

Extended strategic collaboration to leverage Pharmakea's drug discovery platform and small-molecule therapies targeting fibrotic diseases

Celgene committed $9M to extend the collaboration for nine months

11/21/16

Daiichi Sankyo Co. Ltd. (Tokyo)

Portola Pharmaceuticals Inc. (South San Francisco)

$33

Expanded clinical collaboration agreement to develop Andexxa (andexanet alfa) as an antidote for Daiichi's edoxaban

Portola will receive a $15M up-front payment and is eligible to receive up to an additional $10M upon meeting site initiation and enrollment targets; upon Andexxa's approval, Daiichi Sankyo will be eligible to receive a low single-digit royalty on product sales up to a total of $8M

11/2/16

Enamine Ltd. (Kiev, Ukraine)

Pcovery ApS (Copenhagen)

N/A

Extended collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development

Financial terms were not disclosed

11/23/16

Gilead Sciences Inc. (Foster City, Calif.)

Globeimmune Inc. (Louisville, Colo.)

N/A

Globeimmune ended its license agreement with Gilead for hepatitis B virus candidate, GS-4774

The company delisted its common shares in July, following a move in May to retain Cantor Fitzgerald & Co. to help explore strategic options; last year, the therapeutic vaccine failed to produce a reduction in hepatitis B surface antigen at week 24 in patients with chronic HBV on long-term viral suppression with oral antiviral therapy

11/21/16

Merck KGaA (Darmstadt, Germany)

Biomed X GmbH (Heidelberg, Germany)

N/A

Research group at the Biomed X Innovation Center, titled "DNA Damage in Cancer," which marks an extension of their ongoing collaboration in the field of oncology research

The aim of the new research team is to develop approaches to exploit cellular DNA damage and repair mechanisms that occur during radiation and radiochemotherapy

11/4/16

Sanofi Pasteur (unit of Sanofi SA; Paris)

Merck & Co. Inc. (Kenilworth, N.J.)

N/A

Companies are closing their vaccines joint venture, Sanofi Pasteur MSD, following clearances recently granted by the European Commission

Beginning Jan. 1, the two will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines businesses into their operations

11/28/16

Sanofi SA (Paris)

Selecta Biosciences Inc. (Watertown, Mass.)

N/A

Agreement in which worldwide rights go to Selecta for intellectual property, data and materials generated through a discovery collaboration initiated and funded by Sanofi for the development of candidates to treat peanut allergy and celiac disease

The move followed Sanofi's strategic review of its R&D portfolio, which resulted in a decision to exit the collaboration; the transition of the discovery programs is not expected to have a material impact on Selecta's cash runway

11/11/16

Sanofi SA (Paris)

Alnylam Pharmaceuticals Inc. (Cambridge, Mass.)

$75

Pursuant to a global alliance inked in January 2014, Sanofi's Genzyme unit is opting to co-develop and co-commercialize fitusiran, an RNAi therapeutic to treat hemophilia and rare bleeding disorders in the U.S., Canada and Western Europe

That expanded right is in addition to Sanofi's previously exercised opt-in decision to develop and commercialize fitusiran in their rest of world territories; certain development and sales and marketing costs for fitusiran will be shared 50/50 between Sanofi Genzyme and Alnylam; Sanofi Genzyme will be required to make payments totaling up to $75M upon the achievement of development and regulatory milestones for fitusiran; upon the initiation of the first global phase III trial for fitusiran, expected to start next year, Alnylam will earn a milestone payment of $25M; Sanofi Genzyme also will be required to pay tiered double-digit royalties up to 20% on annual fitusiran net sales in its territory; the companies will share profits equally in the co-commercialization territory, where Alnylam expects to book product sales

11/15/16

Voyager Therapeutics Inc. (Cambridge, Mass.)

Regenxbio Inc. (Rockville, Md.)

N/A

Voyager exercised commercial options for the use of NAV vectors to develop and commercialize gene therapies for neurological diseases

Regenxbio will receive undisclosed up-front payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property

11/30/16

December

Biodelivery Sciences International Inc. (Raleigh, N.C.)

Endo Pharmaceuticals Inc. (Dublin)

N/A

Terminated licensing deal for Belbuca (buprenorphine) buccal film

The transaction follows a strategic decision made by Endo regarding its U.S. branded pain business

12/9/16

Merck & Co. Inc. (Kenilworth, N.J.)

Biothera Pharmaceuticals Inc. (Eagan, Minn.)

N/A

Expanded research collaboration to include a phase II study investigating Biothera's Imprime PGG in combination with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in second- and third-line patients with head and neck squamous cell cancer

The goal of the new study will be to determine the potential of Imprime PGG, a pathogen-associated molecular patterning molecule designed to increase patient responses to Keytruda

12/6/16

Merck KGaA (Darmstadt, Germany)

Roche Holding AG (Basel, Switzerland)

N/A

Distribution alliance to include the polymerase chain reaction and quantitative real-time PCR enzyme products of Kapa Biosystems

Milliporesigma, of Billerica, Mass., similarly expanded its distribution alliance with Roche to include Kapa's PCR and qPCR enzyme products; financial details were not disclosed in either transaction

12/2/16

Synpromics Ltd. (Edinburgh, Scotland)

Adverum Biotechnologies Inc. (Menlo Park, Calif.)

N/A

Expanded research collaboration to use Sympromics' PromPT technology to develop promoters that specifically regulate gene expression in certain types of liver cells

The research collaboration began in December 2015 and was initially focused on using Synpromics' technology to develop promoters for the treatment of eye diseases

12/8/16

Synpromics Ltd. (Edinburgh, Scotland)

Adverum Biotechnologies Inc. (Menlo Park, Calif.)

N/A

Expanded research collaboration to use Sympromics' PromPT technology to develop promoters that specifically regulate gene expression in certain types of liver cells

The research collaboration began in December 2015 and was initially focused on using Synpromics' technology to develop promoters for the treatment of eye diseases

12/8/16

Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.

For more information about individual companies and/or products, see Thomson Reuters Cortellis.

 

No Comments